Antibiotics risks another 'lost decade' as patent filings lag behind

16 June 2015
lots-of-pills-big

The antibiotics market is badly neglected and risks another lost decade, while research into rare diseases continues at a rapid pace, according to a new report from intellectual property firm Marks & Clerk.

Less than 5% of patents filed for antibiotic research since 2004 are focused in new classes of antibiotics, and the study showed that Amgen (Nasdaq: AMGN) is the lead filer of patents relating to new antibiotics. The levels of patent filing in antibiotics are much lower than in rare diseases, though there has been a gradual increase in numbers year-on-year since 2009.

Marks & Clerk found that the top two filers of antibiotic patents are Chinese companies, Tianjin Shengi Group, and Shandong Xuanzhu Pharmaceutical Technology, but universities are also key in this field: the Universities of California and Texas are the third and eighth highest filers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical